Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is primarily characterized by the presence of airflow limitation resulting from parenchymal destruction (emphysema) and airway remodeling \[[@CR1]\]. Therefore, the mainstay of pharmacological treatment in stable COPD are bronchodilators, such as long-acting β~2~-adrenoceptor agonists (β~2~-agonists) and long-acting muscarinic antagonists \[[@CR2]\]. These bronchodilators have been shown to improve symptoms, quality-of-life, pulmonary function and mortality in patients with COPD.

COPD cases are often complicated by lung cancer, because both conditions are strongly associated with cigarette smoking \[[@CR3]\]. With the improvement in mortality from COPD itself due to bronchodilators, lung cancer has come to be one of the most important problems in COPD. Surgical operation is the first-choice treatment in COPD patients with resectable lung cancer. However, atrial arrhythmias often occur as a postoperative complication following thoracic surgery \[[@CR4]\] and may be associated with an increased risk of cerebral embolism, since the administration of anticoagulation therapy must be balanced against the risk of bleeding. Therefore, postoperative atrial arrhythmias should be avoided in COPD patients with lung cancer who undergo surgical resection.

There are several reasons why atrial arrhythmias often occur after surgical operation for lung cancer in COPD patients. One is that COPD itself is a risk factor for postoperative atrial arrhythmias \[[@CR5]\]. Another reason is that lung cancer surgery also entails a risk of postoperative atrial arrhythmias. According to recent studies, the arrhythmias result from the synergic action of increased vagal tone, atrial inflammation, pulmonary hypertension, right heart strain, hypoxemia, and anatomical substrate, such as surgical damage to the cardiac plexus or to the proximal trunks of the pulmonary veins \[[@CR6], [@CR7]\]. Moreover, several reports have shown that β~2~-agonists increase the risk of atrial arrhythmias in COPD patients who do not undergo surgery \[[@CR8], [@CR9]\]. However, the effects of β~2~-agonists treatment during the perioperative period on postoperative atrial arrhythmias after lung cancer surgery have not been elucidated.

The aim of this study was to investigate whether perioperative β~2~-agonists treatment would increase the risk of postoperative atrial arrhythmias after pulmonary resection for non-small-cell lung cancer (NSCLC) in chronic obstructive pulmonary disease patients.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

We conducted a retrospective analysis of the COPD patients diagnosed with NSCLC who underwent surgery at the Tazuke Kofukai Medical Research Institute, Kitano Hospital, between January 2007 and December 2014. The exclusion criteria were as follows: no pathological confirmation of NSCLC, lesser resection (wedge resection), repeated pulmonary resection, pneumonectomy, chronic atrial arrhythmias before surgery, evidence of infection such as pneumonia before surgery, thyroid dysfunction, and renal failure requiring hemodialysis \[[@CR10]--[@CR12]\]. COPD was diagnosed on the basis of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) \[[@CR13]\]. The results of the perioperative β~2~-agonists treatment group (β~2~-agonists group) and non-β~2~-agonists treatment group (control group) were compared and analyzed regarding postoperative cardiopulmonary complications. The patients were on continuous electrocardiogram monitoring from surgery day to a week after surgery. After a week, we evaluate postoperative cardiopulmonary complications by intermittent monitoring and examinations. In the perioperative β~2~-agonists treatment group, the subjects received tulobuterol tape (2 mg/day), inhaled indacaterol (150 μg/day), or inhaled salmeterol (100 μg/day) from more than 2 weeks before surgery until at least a month after surgery, without interruption. The data from the respiratory function tests performed before and after perioperative β~2~-agonists treatment were compared in the few cases where such data were tracked.

Study approval was granted by the ethics committee of the Tazuke Kofukai Medical Research Institute, Kitano Hospital, in accordance with the Declaration of Helsinki.

Surgical procedure {#Sec4}
------------------

All patients underwent lobectomies or segmentectomies with anterolateral thoracotomy, posterolateral thoracotomy, or video-assisted thoracic surgery (VATS). For VATS, three access ports were placed through 2--3 cm axillary skin incisions. One of these incisions was extended by 4--5 cm, and the resected lung was removed in a plastic bag without using a rib spreader. Patients requiring conversion from VATS to thoracotomy were classified as open thoracotomy patients.

Postoperative cardiopulmonary complications {#Sec5}
-------------------------------------------

All patients were followed-up after surgery, and complications occurring during the same hospitalization as the index procedure were recorded. Cardiopulmonary complications were defined as previously described \[[@CR10]\] and included cardiovascular complications, such as arrhythmias (atrial fibrillation \[AF\], paroxysmal supraventricular tachycardia \[PSVT\], ventricular tachycardia \[VT\]), angina pectoris, acute myocardial infarction (AMI), congestive heart failure (CHF), thromboembolic events; and respiratory complications such as pneumonia (fever \>38 °C, purulent sputum, abnormal findings on chest X-ray), atelectasis with bronchoscopic therapy, acute respiratory distress syndrome (ARDS) (partial pressure of oxygen in arterial blood-fraction of inspired oxygen \<300 mmHg), respiratory insufficiency requiring tracheostomy, and respiratory failure requiring mechanical ventilation. As prolonged air leak and bronchopleural fistulas are considered surgical factors, they were excluded.

Endpoints {#Sec6}
---------

The primary endpoint was the incidence of postoperative atrial arrhythmias (AF and PSVT) after surgical resection. Secondary endpoint was the incidence of the other cardiopulmonary complications after surgical resection.

Statistical analysis {#Sec7}
--------------------

The data are presented as mean ± standard deviation. Categorical variables are shown as percentages of the sample. Continuous variables were compared using the Welch's *t* test and categorical variables using the Fisher's exact test or chi-squared test. Propensity score matching was applied to balance the assignment of patients for correct evaluation of the effects of β~2~-agonists treatment during the perioperative period. The variables were age, gender, comorbidities, smoking history, operation procedure, lung-cancer staging, and respiratory function. Univariate logistic regression analyses were performed for postoperative atrial arrhythmias to observe Type 1 error. We assessed the time free of postoperative atrial arrhythmias using Kaplan--Meier analysis. Differences between term curves were tested for statistical significance using the two-tailed log-rank test. All data were processed and analyzed using SPSS version 20.0 (SPSS, Chicago, IL, USA) or the statistical software R version 3.0.3 (R Foundation for statistical computing, Vienna, Austria). All *P*-values are 2-sided, and *P*-values \< 0.1 were considered statistically significant.

Results {#Sec8}
=======

Subjects {#Sec9}
--------

Data from the 191 COPD patients diagnosed with NSCLC who underwent surgery at our hospital between January 2007 and December 2014 were obtained from the hospital's database. Seventeen patients were excluded because of lesser resection (wedge resection) (*n* = 4), pneumonectomy (*n* = 8), and chronic atrial arrhythmias before surgery (*n* = 5). Thus, 174 patients were included in this study. The clinicopathological characteristics of patients are shown in Table [1](#Tab1){ref-type="table"}. There were no significant differences in age, gender, comorbidities, smoking history, surgical procedure, or lung cancer staging between the perioperative β~2~-agonists group and the control group. However, there were statistically significant differences between the two groups in forced expiratory volume in 1 s (FEV~1~) and the ratio of FEV~1~ to forced vital capacity (FVC). Furthermore, %FEV~1~ after administration of β~2~-agonists was significantly increased compared with %FEV~1~ before administration of β~2~-agonists (Fig. [1](#Fig1){ref-type="fig"}).Table 1Characteristics of patients with chronic obstructive pulmonary diseaseβ~2~-agonists group (*n* = 71)Control group (*n* = 103)*P*-valueAge, years71.4 ± 7.370.7 ± 8.60.523Gender (male)55 (76%)80 (78%)0.975Comorbidities (HT/DL/DM/IHD)20/8/9/329/15/15/7NSSmoking history65 (92%)93 (90%)0.778Surgical procedure (VATS)26 (37%)49 (48%)0.152Lung cancer staging (I/II/III/IV)48/8/13/268/9/22/4NSVC, % predicted94.9 ± 14.698.0 ± 16.70.186FEV~1~, % predicted69.6 ± 15.179.0 ± 17.0\<0.001FEV~1~/FVC, %57.9 ± 8.662.9 ± 6.8\<0.001Values are shown as numbers (%) or mean ± SDAbbreviations: *DL* dyslipidemia, *DM* diabetes mellitus, *FEV* ~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *HT* hypertension, *IHD* ischemic heart disease, *NS* not significant, *VATS* video-assisted thoracoscopic surgery, *VC* vital capacity Fig. 1A comparison of percentage forced expiratory volume in 1 s (%FEV~1~) before and after perioperative treatment with long-acting β~2~-adrenoceptor agonists (β~2~-agonists). %FEV~1~ improved significantly after perioperative β~2~-agonists treatment (*P* \< 0.001)

Postoperative cardiopulmonary complications {#Sec10}
-------------------------------------------

Postoperative cardiopulmonary complications are shown in Table [2](#Tab2){ref-type="table"}. Atrial arrhythmias (AF and PSVT) were the most frequent complication. There were no events of VT, angina pectoris, CHF, or ARDS. There were no statistically significant differences between the two groups in the incidence of cardiovascular complications, AF, PSVT, AMI, thromboembolic events, respiratory complications, pneumonia, atelectasis, respiratory insufficiency, or respiratory failure.Table 2Postoperative cardiopulmonary complicationsβ~2~-agonists group (*n* = 71)Control group (*n* = 103)*P*-valueCardiovascular complications7 (10%)10 (10%)0.974 Atrial arrhythmias7 (10%)8 (8%)0.629  Atrial fibrillation7 (10%)7 (7%)0.465  Paroxysmal supraventricular tachycardia01 (1%)0.405 Acute myocardial infarction01 (1%)0.405 Thromboembolic events02 (2%)0.238Respiratory complications9 (13%)11 (11%)0.685 Pneumonia5 (7%)5 (5%)0.542 Atelectasis with bronchoscopic therapy4 (6%)4 (4%)0.588 Respiratory insufficiency requiring tracheostomy01 (1%)0.405 Respiratory failure requiring mechanical ventilation1 (1%)3 (3%)0.515

Evaluation of postoperative atrial arrhythmias between perioperative β~2~-agonists treatment group and control group using propensity score-matched analysis {#Sec11}
------------------------------------------------------------------------------------------------------------------------------------------------------------

Propensity score matching was used and variables such as age, gender, comorbidities, smoking history, operation procedure, lung cancer staging, and respiratory function were included, because it was possible that these factors affected the incidence of postoperative cardiopulmonary complications \[[@CR11]\]. The perioperative β~2~-agonists treatment group and control group were well matched (67 patients each), without significant differences in clinical factors (Table [3](#Tab3){ref-type="table"}). The effect size and bias reduction were shown in Table [4](#Tab4){ref-type="table"}. The effect sizes and the mean bias reduction were well validated. There were no statistically significant differences between the two groups in the limited analysis of patients with cardiopulmonary complications including atrial arrhythmias (Table [5](#Tab5){ref-type="table"}). Univariate logistic regression analyses showed there were no statistically significant associations between atrial arrhythmias and other cardiopulmonary complications (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Kaplan--Meier analysis was performed to determine whether perioperative β~2~-agonists treatment had an effect on postoperative atrial arrhythmias after lung cancer surgery in the COPD patients. There were no statistically significant differences between the two groups in the time free of postoperative atrial arrhythmias (*P* = 0.573; Fig. [2](#Fig2){ref-type="fig"}).Table 3Propensity score-matched comparison of clinical factorsVariablesβ~2~-agonists group (*n* = 67)Control group (*n* = 67)*P*-valueAge, years71.4 ± 7.470.5 ± 8.50.503Gender (male)53 (79%)52 (78%)0.834Comorbidities (HT/DL/DM/IHD)19/8/9/318/9/10/3NSSmoking history61 (91%)59 (88%)0.572Surgical procedure (VATS)22 (33%)29 (43%)0.213Lung cancer staging (I/II/III/IV)46/7/12/242/6/16/3NSVC, % predicted95.7 ± 14.297.6 ± 16.90.475FEV~1~, % predicted70.6 ± 14.975.0 ± 17.00.108FEV~1~/FVC, %58.2 ± 8.660.2 ± 7.00.145Values are shown as numbers (%) or mean ± SDAbbreviations as in Table [1](#Tab1){ref-type="table"} Table 4The effect size and bias reductionβ~2~-agonists groupControl groupLogistic regression analysis*n* = 71*n* = 103Difference of meansStandard error*P*-valueEffect sizeBias reductionAge71.4 ± 7.370.7 ± 8.60.70.860.520.82VC, % predicted94.9 ± 14.698.0 ± 16.7−3.11.690.191.84FEV~1~, % predicted69.6 ± 15.179.0 ± 17.0−9.41.73\<0.0015.42FEV~1~/FVC, %57.9 ± 8.662.9 ± 6.8−5.00.85\<0.0015.92Logistic regression analysis adjusted propensity score*n* = 67*n* = 67Age71.4 ± 7.470.5 ± 8.50.90.970.500.93113.4VC, % predicted95.7 ± 14.297.6 ± 16.9−1.91.900.471.0054.5FEV~1~, % predicted70.6 ± 14.975.0 ± 17.0−4.41.950.112.2641.6FEV~1~/FVC, %58.2 ± 8.660.2 ± 7.0−2.00.950.142.1035.5Mean of bias reduction61.3*Abbreviations*: *FEV* ~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *VC* vital capacity Table 5Postoperative cardiopulmonary complications using propensity score-matched analysisVariablesβ~2~-agonists group (*n* = 67)Control group (*n* = 67)*P*-valueCardiovascular complications6 (9%)9 (13%)0.411 Atrial arrhythmias6 (9%)8 (12%)0.572  Atrial fibrillation6 (9%)7 (10%)0.770  Paroxysmal supraventricular tachycardia01 (2%)0.316 Acute myocardial infarction01 (2%)0.316 Thromboembolic events01 (2%)0.316Respiratory complications9 (13%)8 (12%)0.795 Pneumonia5 (8%)3 (5%)0.466 Atelectasis with bronchoscopic therapy4 (6%)4 (6%)1.000 Respiratory insufficiency requiring tracheostomy001.000 Respiratory failure requiring mechanical ventilation1 (2%)1 (2%)1.000 Fig. 2Kaplan--Meier analyses of the incidence of postoperative atrial arrhythmias in the patients after propensity score matching, stratified by perioperative treatment with long-acting β~2~-adrenoceptor agonists (β~2~-agonists). There were no statistically significant differences between the two groups in the time free of postoperative atrial arrhythmias (*P* = 0.573)

Power calculation {#Sec12}
-----------------

We calculated that a two-tailed *t* test with a 10% significance level and 80% power would require 2095 patients for the primary endpoint of the present study. Therefore, 174 patients (β~2~-agonists group: 71 and control group: 103, and incidence of atrial arrhythmias of the subjects β~2~-agonists group: 7 and control group: 8) in the present study were considered low power.

Discussion {#Sec13}
==========

In this retrospective observational study, the perioperative administration of β~2~-agonists did not increase the incidence of postoperative atrial arrhythmias (AF and PSVT) after surgical resection for NSCLC in patients with COPD. The incidence of other postoperative cardiopulmonary complications such as VT, angina pectoris, AMI, CHF, thromboembolic events, pneumonia, atelectasis, ARDS, respiratory insufficiency and respiratory failure was also not increased by the perioperative administration of β~2~-agonists.

β~2~-agonists are among the first-choice drugs for the treatment of patients with stable COPD \[[@CR2]\]. Several reports have shown that treatment with β~2~-agonists increased the risk of atrial arrhythmias in stable COPD patients \[[@CR8], [@CR9]\]. The mechanism involves β~2~-agonists's stimulation of the β~1~-adrenoceptor of the cardiac conduction system. β~2~-agonists are usually administered using inhaler devices and have high selectivity for the β~2~-adrenoceptor \[[@CR14]\]. However, they can cause adverse systemic effects, such as atrial arrhythmias, by migrating from lung to blood and stimulating the β~1~-adrenoceptor of the cardiac conduction system.

On the other hand, β~2~-agonists may have various beneficial effects on atrial arrhythmias. First, postoperative atrial arrhythmias are considered to result from right heart strain \[[@CR6], [@CR7]\]. β~2~-agonists have a strong bronchodilation effect that leads to amelioration of right heart strain by modifying the hyperinflation in patients with stable COPD \[[@CR15]\]. Therefore, the bronchodilation of β~2~-agonists may reduce the risk of atrial arrhythmias in patients with stable COPD. Second, in the perioperative period, a low predicted postoperative FEV~1~ has been shown to be the best indicator of patients at high risk for pulmonary resection surgery \[[@CR16]\]. Suzuki et al. showed that significant FEV~1~ improvement was observed after the use of perioperative bronchodilator treatment in lung cancer patients with COPD \[[@CR17]\]. In the present study, %FEV~1~ improved significantly after perioperative β~2~-agonists treatment in the few cases whose data was tracked (*P* \< 0.001; Fig. [1](#Fig1){ref-type="fig"}). Therefore, perioperative β~2~-agonists treatment might improve FEV~1~, resulting in a protective effect against postoperative cardiopulmonary complications such as atrial arrhythmias. These harmful and beneficial effects of β~2~-agonists on atrial arrhythmias might cancel each other out. In the present study, the perioperative administration of β~2~-agonists did not increase the incidence of postoperative atrial arrhythmias after surgical resection for NSCLC in patients with COPD.

The incidence rate of atrial arrhythmias after pulmonary resection in the present study was about 9%. Compared with other studies (10--12%) \[[@CR18], [@CR19]\], this rate was a little low. Because the patients having risk factors of atrial arrhythmias were excluded in the criteria, low incidence rate of atrial fibrillation might be found.

We acknowledge limitations of the present study. First, the present study was retrospective. Second, the present study was limited by being merely a small sample size and low power to investigate the effect of β~2~-agonists on atrial arrhythmias, rather than a randomized controlled interventional trial. To compensate for these limitations, we performed a propensity score matching analysis. These analyses indicated that perioperative β~2~-agonists treatment was not correlated with the risk of postoperative atrial arrhythmias in COPD patients with NSCLC.

Conclusions {#Sec14}
===========

This study showed that the association between perioperative β~2~-agonists treatment and the risk of postoperative atrial arrhythmias after pulmonary resection for NSCLC in COPD patients. Perioperative administration of β~2~-agonists might not increase the incidence of postoperative atrial arrhythmias after surgical resection for NSCLC in COPD patients. Further prospective studies with a larger number of patients from multiple institutions will be required to confirm the present findings.

Additional file {#Sec15}
===============

Additional file 1: Table S1.Univariate logistic regression analysis for postoperative atrial arrhythmias after propensity score-matched analysis (DOCX 17 kb)

AF

:   Atrial fibrillation

AMI

:   Acute myocardial infarction

ARDS

:   Acute respiratory distress syndrome

CHF

:   Congestive heart failure

COPD

:   Chronic obstructive pulmonary disease

FEV~1~

:   Forced expiratory volume in 1 s

FVC

:   Forced vital capacity

GOLD

:   Global Initiative for Chronic Obstructive Lung Disease

NSCLC

:   Non-small-cell lung cancer

PSVT

:   Paroxysmal supraventricular tachycardia

VATS

:   Video-assisted thoracoscopic surgery

VT

:   ventricular tachycardia
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